Risk stratification by considering history of thrombosis, JAK2 and MPL mutations, and age can be beneficial, and treatment can be planned accordingly.16 Treatment for essential thrombocytosis includes cytoreductive therapy with hydroxyurea. The gene discussed is JAK2; the disease is essential thrombocythemia.